Author

Camille Cosson

Lyon 1 UniversitéORCID 0000-0002-7402-457XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Assay:metagenomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Bénédicte F. PyiD· 2 shared A. DuquesneiD· 1 shared Agnès TissieriD· 1 shared Alexandre BélotiD· 1 shared Alexandre Thibault Jacques MariaiD· 1 shared Amaury ReyiD· 1 shared Anne PagnieriD· 1 shared Anne‐Laure HuberiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Bénédicte F. PyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintFeb 28, 2026

CRY-NLRP3 complexes define a circadian checkpoint controlling inflammasome activation

Léa Bardoulet, Delphine Burlet, Hubert B. Leloup…·Anne‐Laure Huber

This study identifies CRY-NLRP3 complexes as a circadian checkpoint that modulates inflammasome activation and drug response, showing time-of-day effects on inflammation and drug efficacy.

DOI 10.64898/2026.02.26.708242

humanproteomics

𝕏 PostBluesky

ImmunologyThe Journal of Experimental MedicinePeer-reviewedFeb 28, 2024

Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.

Camille Cosson, Romane Riou, Danish Patoli…·Bénédicte F. Py

This study functionally characterizes 34 NLRP3 variants associated with CAPS, identifying functional diversity and inhibitor sensitivity, with implications for diagnosis and drug development.

56 citationstop 2%

humanexperimental assay

𝕏 PostBluesky